Talipexole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Talipexole
Talipexole.svg
Systematic (IUPAC) name
6-allyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-d]azepin-2-amine
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
  • Prescription only
Routes Oral
Identifiers
CAS number 36085-73-1 N
ATC code None
PubChem CID 5374
ChemSpider 5181 N
UNII 7AM2J46Z1Y N
ChEMBL CHEMBL1289023 N
Chemical data
Formula C10H15N3S 
Mol. mass 209.31 g/mol
 N (what is this?)  (verify)

Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]

Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.[3]

The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]:15

References[edit]

  1. ^ PharmaLetter 22 July 1996 First Launch In Japan For Talipexole
  2. ^ EvaluatePharma Database. Page accessed 9 December 2014
  3. ^ a b Benkert O, et al. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. PMID 8775758
  4. ^ Japanese Ministry of Health, Labour and Welfare March 2008 Pharmaceuticals and Medical Devices Safety Information No. 245